Even if UTX loss was recently reported to sensitize MM cell lines to EZH2 inhibition [35], neither EZH2 gene expression nor UTX mutation status was predictive of MM cell response to PRC2 targeting in our collection of MM cell lines representative of molecular heterogeneity or in the primary samples tested. This evidence concerns the gene KDM6A and Miyoshi myopathy.